Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founder & CEO, of Mydecine Innovations Group, Josh Bartch.
Similar Posts
Exploring Healing and Embodiment: Insights from The Body Workshop
In a world where wellness encompasses more than just physical health, The Body Workshop offers a unique platform for exploring the interconnectedness of mind, body, and spirit.
Does Jon Stewart Microdose Magic Mushrooms? | Plus Pirate Eye
Does Jon Stewart Microdosing Magic Mushrooms?
Have you ever wanted to try microdosing magic mushrooms before, because Jon Stewart wants to! On a recent podcast episode of The Problem with Jon Stewart, the political comedian opened his show by saying “I’ve been microdosing the whole week!”, before clarifying that he just WANTS to try psychedelic microdosing.
The satirist, sometimes known as America’s Conscience, is one of the most influential voices in media over the last 3 decades. His short and funny forrow into the psychedelics debate should help further propel the issue into the mainstream.
Can microdosing help depression? Can Microdosing help mental health? Jon Stewart thinks so, though this claim needs to be verified by the medical establishment.
Microdosing has become a popular trend for professionals in the last few decades, so it is not surprising that Jon Stewart knows about it. He is a man with his finger on America’s pulse.
Link to podcast: https://open.spotify.com/episode/3OZV5DLbn33bNSUluLS7oX?si=qVoGF4cCS76x_MrM9h_slw
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
#jonstweart #thejonsteartproblem #psychedelics
Riley Cote – From NHL Enforcer to Psychedelic Therapy Advocate
On this episode of the Psychedelic Spotlight Podcast, our host David Flores catches up with former Philadelphia Flyer and NHL enforcer, Riley Cote who in recent years has become one of the most prominent and outspoken advocates for psychedelics and psychedelic-assisted therapy through his work with the Wake Network and RileyCote.com.
Interview With Christi Myers
In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.
Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward
When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.
In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.
Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/
MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/
Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #MindMed #Cybin
Could Psilocybin End Our Addiction Crisis?
Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.